Sporadic and neurofibromatosis type 2-associated meningioma in children and adolescents

J Neurooncol. 2023 Jul;163(3):555-563. doi: 10.1007/s11060-023-04344-0. Epub 2023 Jul 4.

Abstract

Purpose: Pediatric meningioma differs not only in its rare incidence from the adult meningioma, but also in its clinical characteristics. Many treatment approaches of pediatric meningioma are based on the study results of adult meningioma studies. The aim of this study was to explore the clinical and epidemiological characteristics of pediatric meningioma.

Methods: Data on pediatric patients diagnosed between 1982 and 2021 with NF2-associated or sporadic meningioma and recruited in the trials/registries HIT-ENDO, KRANIOPHARYNGEOM 2000/2007 and KRANIOPHARYNGEOM Registry 2019 were retrospectively analyzed for clinical characteristics, etiology, histology, therapy, and outcome.

Results: One hundred fifteen study participants were diagnosed with sporadic or NF2-associated meningioma at a median age of 10.6 years. There was a 1:1 sex ratio, with 14% of study participants suffering from NF2. 46% of the meningiomas were located hemispherically, 17% at the optic nerve/ intraorbital and 10% ventricularly. Multiple meningiomas were detected in 69% of NF2 patients and in 9% of sporadic meningiomas. 50% of the meningiomas were WHO grade I, 37% WHO grade II and 6% WHO grade III. Progressions or recurrences occurred after a median interval of 1.9 years. Eight patients (7%) died, 3 of them due to disease. The event-free survival was higher for WHO grade I than for WHO grade II meningioma patients (p = 0.008).

Conclusions: The major difference to the preceding literature could be found in the distribution of different WHO grades and their influence on event-free survival. Prospective studies are warranted to assess the impact of different therapeutic regimens.

Clinical trial registration numbers: NCT00258453; NCT01272622; NCT04158284.

Keywords: Meningioma; Neurofibromatosis; Pediatric brain tumor; Sporadic.

MeSH terms

  • Adolescent
  • Adult
  • Child
  • Disease Progression
  • Humans
  • Meningeal Neoplasms* / epidemiology
  • Meningeal Neoplasms* / therapy
  • Meningioma* / epidemiology
  • Meningioma* / therapy
  • Neurofibromatosis 2* / complications
  • Neurofibromatosis 2* / epidemiology
  • Neurofibromatosis 2* / therapy
  • Retrospective Studies

Associated data

  • ClinicalTrials.gov/NCT04158284
  • ClinicalTrials.gov/NCT00258453
  • ClinicalTrials.gov/NCT01272622